ImmunoGen (IMGN) Azione Prezzo
ImmunoGen Prezzo
Negli ultimi 19 anni ImmunoGen ha aumentato il fatturato del 13,5% all'anno, raggiungendo 287,61 Mio. USD. Per ImmunoGen, il margine netto del -25,6% risulta in aumento rispetto al -148,4% di alcuni anni fa.
ImmunoGen Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
ImmunoGen Azione e analisi azionaria
Domande frequenti sull'azione ImmunoGen
The business model of ImmunoGen Inc is focused on the development of targeted antibody-drug conjugates (ADCs) for the treatment of cancer. ADCs leverage the specificity of antibodies to selectively deliver potent cytotoxic drugs to cancer cells, aiming to minimize side effects. ImmunoGen's proprietary technology, known as ADC technology, involves the use of monoclonal antibodies that target specific proteins overexpressed on cancer cells. These antibodies are conjugated with cytotoxic agents to create ADCs, which bind to cancer cells, allowing for targeted delivery of the drug payload. By advancing its technology and collaborations, ImmunoGen aims to provide innovative treatment options for patients with cancer.
ImmunoGen Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of ImmunoGen Inc in the market include pharmaceutical companies such as Roche Holding AG, Pfizer Inc, and Bristol-Myers Squibb Company.
ImmunoGen Inc is a pharmaceutical company founded in 1981 and headquartered in Waltham, Massachusetts. With a focus on developing targeted antibody-drug conjugates (ADCs), ImmunoGen has been a pioneer in the field of cancer therapeutics. The company's innovative technology aims to deliver treatment directly to cancer cells while minimizing damage to healthy cells. ImmunoGen has partnered with various pharmaceutical companies to accelerate the development and commercialization of ADCs. Over the years, ImmunoGen has gained recognition for its expertise in ADC research and continues to advance its pipeline of novel therapies, making significant contributions to the field of oncology.
ImmunoGen Inc has achieved several significant milestones. The company successfully developed and obtained FDA approval for its targeted anti-cancer therapy, Kadcyla. This milestone revolutionized the treatment of HER2-positive breast cancer, providing a more effective and less toxic treatment option. ImmunoGen Inc also partnered with leading pharmaceutical companies like Roche, Amgen, and Takeda, further validating their novel technology platform. Additionally, the company has made notable progress in advancing their pipeline candidates, including IMGN632 and IMGN151, targeting various hematological malignancies. These achievements demonstrate ImmunoGen Inc's commitment to groundbreaking research and the potential to significantly impact cancer treatment.
ImmunoGen Inc, a leading biotechnology company, primarily operates in the United States. With its headquarters located in Waltham, Massachusetts, ImmunoGen Inc primarily focuses on the development and commercialization of innovative antibody-drug conjugate (ADC) therapies for the treatment of various types of cancer. By leveraging its proprietary technology platform, ImmunoGen Inc has gained recognition and presence in the US healthcare industry. As a US-based company, ImmunoGen Inc has been actively involved in collaborations and partnerships with other biopharmaceutical companies to expand its global reach and potentially introduce its revolutionary ADC therapies to patients worldwide.
ImmunoGen Inc represents values of innovation, dedication, and patient-centricity. With a strong corporate philosophy focused on developing targeted cancer therapies, ImmunoGen is committed to improving the lives of patients battling cancer. By harnessing the power of its unique Antibody-Drug Conjugate (ADC) technology, ImmunoGen strives to deliver transformative treatments that specifically target cancer cells while sparing healthy cells. The company's dedication to research, collaboration, and delivering breakthrough therapies sets it apart in the biotechnology industry. ImmunoGen Inc prioritizes patient well-being and relentlessly pursues advancements in precision medicine to shape the future of cancer treatment.
19 analisti valutano attualmente l’azione ImmunoGen: 7 raccomandano l’acquisto, 12 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per ImmunoGen ricavi pari a 757,20 Mio. USD e un utile per azione di 0,75 USD.
L’azione ImmunoGen (IMGN) è quotata su 8 borse, tra cui: NASDAQ (IMGN), London (0A8K.L), SIX (Zürich) (IMU.SW), XETRA (IMU.DE), Frankfurt (IMU.F), München (IMU.MU), Düsseldorf (IMU.DU).
ImmunoGen Inc is a biotechnology company specializing in the development of innovative therapy approaches for the treatment of cancer. The company's business model is based on the discovery and development of drugs that selectively destroy cancer cells while sparing the surrounding healthy tissue. ImmunoGen utilizes its own technology platform called Antibody-Drug Conjugates (ADCs) for this purpose. ADCs are a new class of drugs that can target cancer cells specifically. They consist of three components: an antibody that binds specifically to cancer cells, a drug that kills the cancer cells, and a linker that connects the two components. By combining these components, ADCs enable targeted tumor destruction and reduce the burden on healthy tissue. ImmunoGen's flagship product is the ADC candidate Mirvetuximab Soravtansine, which is currently being tested in Phase 3 clinical trials for the treatment of ovarian cancer. Mirvetuximab Soravtansine has higher efficacy and fewer side effects compared to conventional chemotherapeutics. In addition, ImmunoGen is developing other ADC candidates in various stages of clinical development. In addition to ADC development, ImmunoGen also operates a service business focused on the manufacturing and optimization of ADCs for other pharmaceutical companies. ImmunoGen has extensive experience in ADC manufacturing and offers this expertise as a service. Furthermore, ImmunoGen collaborates with other companies and research institutions to further develop and expand the ADC technology platform. Another business area of ImmunoGen is the research and development of new technology platforms. The company continuously invests in the exploration of new approaches for cancer therapy. This includes the ABC technology platform, which aims to improve the short-term stability of ADCs while increasing their efficacy. ImmunoGen aims to become a leading biotechnology company in the field of cancer therapy. With its innovative ADC technology platform and the development of promising candidates like Mirvetuximab Soravtansine, ImmunoGen is on track to achieve this goal. With a broad portfolio of products and services, ImmunoGen is well-equipped to withstand an increasingly complex and volatile industry.
Il attesa fatturato di ImmunoGen ammonta a 757,20 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di ImmunoGen ammonta a 216,89 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il P/E per ImmunoGen non può essere attualmente calcolato.
L'indicatore Price-to-Sales (P/S) per ImmunoGen non può essere calcolato al momento.
Il Quality Score AlleAktien per ImmunoGen è 4/10.
L'ISIN di ImmunoGen è US45253H1014. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di ImmunoGen è 878613. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di ImmunoGen è IMGN. Con questo simbolo di borsa vengono negoziate le azioni ImmunoGen in borsa.
Azione ImmunoGen
Gruppo di pari di ImmunoGen
ImmunoGen Ticker
ImmunoGen FIGI
Altre metriche e analisi di ImmunoGen in Deep Dive.
La nostra analisi azionaria dell'azione ImmunoGen include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di ImmunoGen. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: